HEADER ISOMERASE/IMMUNOSUPPRESSANT 14-OCT-99 1QNH TITLE PLASMODIUM FALCIPARUM CYCLOPHILIN (DOUBLE MUTANT) COMPLEXED WITH TITLE 2 CYCLOSPORIN A COMPND MOL_ID: 1; COMPND 2 MOLECULE: PEPTIDYL-PROLYL CIS-TRANS ISOMERASE; COMPND 3 CHAIN: A, B; COMPND 4 SYNONYM: PPIASE, ROTAMASE, CYCLOPHILIN A; COMPND 5 EC: 5.2.1.8; COMPND 6 ENGINEERED: YES; COMPND 7 MOL_ID: 2; COMPND 8 MOLECULE: CYCLOSPORIN A; COMPND 9 CHAIN: C, D; COMPND 10 SYNONYM: CYCLOSPORINE, CICLOSPORIN, CICLOSPORINE; COMPND 11 ENGINEERED: YES SOURCE MOL_ID: 1; SOURCE 2 ORGANISM_SCIENTIFIC: PLASMODIUM FALCIPARUM; SOURCE 3 ORGANISM_TAXID: 5833; SOURCE 4 EXPRESSION_SYSTEM: ESCHERICHIA COLI; SOURCE 5 EXPRESSION_SYSTEM_TAXID: 469008; SOURCE 6 EXPRESSION_SYSTEM_STRAIN: BL21(DE3); SOURCE 7 MOL_ID: 2; SOURCE 8 SYNTHETIC: YES; SOURCE 9 ORGANISM_SCIENTIFIC: TOLYPOCLADIUM INFLATUM; SOURCE 10 ORGANISM_TAXID: 29910 KEYWDS ISOMERASE-IMMUNOSUPPRESSANT COMPLEX, CYCLOPHILIN-CYCLOSPORIN COMPLEX, KEYWDS 2 CYCLOSPORIN A, IMMUNOSUPPRESSANT, CYCLOPHILIN EXPDTA X-RAY DIFFRACTION AUTHOR M.R.PETERSON,D.R.HALL,W.N.HUNTER REVDAT 5 13-DEC-23 1QNH 1 LINK REVDAT 4 13-JUL-11 1QNH 1 VERSN REVDAT 3 24-FEB-09 1QNH 1 VERSN REVDAT 2 23-JUL-02 1QNH 1 HEADER REVDAT 1 13-OCT-00 1QNH 0 JRNL AUTH M.R.PETERSON,D.R.HALL,M.BERRIMAN,G.A.LEONARD,A.H.FAIRLAMB, JRNL AUTH 2 W.N.HUNTER JRNL TITL THE THREE-DIMENSIONAL STRUCTURE OF A PLASMODIUM FALCIPARUM JRNL TITL 2 CYCLOPHILIN IN COMPLEX WITH THE POTENT ANTI-MALARIAL JRNL TITL 3 CYCLOSPORIN A JRNL REF J.MOL.BIOL. V. 298 123 2000 JRNL REFN ISSN 0022-2836 JRNL PMID 10756109 JRNL DOI 10.1006/JMBI.2000.3633 REMARK 1 REMARK 1 REFERENCE 1 REMARK 1 AUTH M.BERRIMAN,A.H.FAIRLAMB REMARK 1 TITL DETAILED CHARACTERIZATION OF A CYCLOPHILIN FROM THE HUMAN REMARK 1 TITL 2 MALARIA PARASITE PLASMODIUM FALCIPARUM REMARK 1 REF BIOCHEM.J. V. 334 437 1998 REMARK 1 REFN ISSN 0264-6021 REMARK 1 PMID 9716503 REMARK 2 REMARK 2 RESOLUTION. 2.10 ANGSTROMS. REMARK 3 REMARK 3 REFINEMENT. REMARK 3 PROGRAM : CNS 0.5 REMARK 3 AUTHORS : BRUNGER,ADAMS,CLORE,DELANO,GROS,GROSSE- REMARK 3 : KUNSTLEVE,JIANG,KUSZEWSKI,NILGES,PANNU, REMARK 3 : READ,RICE,SIMONSON,WARREN REMARK 3 REMARK 3 REFINEMENT TARGET : NULL REMARK 3 REMARK 3 DATA USED IN REFINEMENT. REMARK 3 RESOLUTION RANGE HIGH (ANGSTROMS) : 2.10 REMARK 3 RESOLUTION RANGE LOW (ANGSTROMS) : 24.00 REMARK 3 DATA CUTOFF (SIGMA(F)) : 0.000 REMARK 3 DATA CUTOFF HIGH (ABS(F)) : NULL REMARK 3 DATA CUTOFF LOW (ABS(F)) : NULL REMARK 3 COMPLETENESS (WORKING+TEST) (%) : 98.2 REMARK 3 NUMBER OF REFLECTIONS : 24606 REMARK 3 REMARK 3 FIT TO DATA USED IN REFINEMENT. REMARK 3 CROSS-VALIDATION METHOD : THROUGHOUT REMARK 3 FREE R VALUE TEST SET SELECTION : RANDOM REMARK 3 R VALUE (WORKING SET) : 0.170 REMARK 3 FREE R VALUE : 0.210 REMARK 3 FREE R VALUE TEST SET SIZE (%) : 10.000 REMARK 3 FREE R VALUE TEST SET COUNT : 2471 REMARK 3 ESTIMATED ERROR OF FREE R VALUE : NULL REMARK 3 REMARK 3 FIT IN THE HIGHEST RESOLUTION BIN. REMARK 3 TOTAL NUMBER OF BINS USED : 49 REMARK 3 BIN RESOLUTION RANGE HIGH (A) : 2.10 REMARK 3 BIN RESOLUTION RANGE LOW (A) : 2.11 REMARK 3 BIN COMPLETENESS (WORKING+TEST) (%) : NULL REMARK 3 REFLECTIONS IN BIN (WORKING SET) : 390 REMARK 3 BIN R VALUE (WORKING SET) : 0.2270 REMARK 3 BIN FREE R VALUE : 0.2420 REMARK 3 BIN FREE R VALUE TEST SET SIZE (%) : 10.00 REMARK 3 BIN FREE R VALUE TEST SET COUNT : 53 REMARK 3 ESTIMATED ERROR OF BIN FREE R VALUE : NULL REMARK 3 REMARK 3 NUMBER OF NON-HYDROGEN ATOMS USED IN REFINEMENT. REMARK 3 PROTEIN ATOMS : 2775 REMARK 3 NUCLEIC ACID ATOMS : 0 REMARK 3 HETEROGEN ATOMS : 0 REMARK 3 SOLVENT ATOMS : 213 REMARK 3 REMARK 3 B VALUES. REMARK 3 FROM WILSON PLOT (A**2) : 34.20 REMARK 3 MEAN B VALUE (OVERALL, A**2) : 26.60 REMARK 3 OVERALL ANISOTROPIC B VALUE. REMARK 3 B11 (A**2) : NULL REMARK 3 B22 (A**2) : NULL REMARK 3 B33 (A**2) : NULL REMARK 3 B12 (A**2) : NULL REMARK 3 B13 (A**2) : NULL REMARK 3 B23 (A**2) : NULL REMARK 3 REMARK 3 ESTIMATED COORDINATE ERROR. REMARK 3 ESD FROM LUZZATI PLOT (A) : NULL REMARK 3 ESD FROM SIGMAA (A) : NULL REMARK 3 LOW RESOLUTION CUTOFF (A) : NULL REMARK 3 REMARK 3 CROSS-VALIDATED ESTIMATED COORDINATE ERROR. REMARK 3 ESD FROM C-V LUZZATI PLOT (A) : NULL REMARK 3 ESD FROM C-V SIGMAA (A) : NULL REMARK 3 REMARK 3 RMS DEVIATIONS FROM IDEAL VALUES. REMARK 3 BOND LENGTHS (A) : 0.006 REMARK 3 BOND ANGLES (DEGREES) : 1.300 REMARK 3 DIHEDRAL ANGLES (DEGREES) : NULL REMARK 3 IMPROPER ANGLES (DEGREES) : NULL REMARK 3 REMARK 3 ISOTROPIC THERMAL MODEL : RESTRAINED REMARK 3 REMARK 3 ISOTROPIC THERMAL FACTOR RESTRAINTS. RMS SIGMA REMARK 3 MAIN-CHAIN BOND (A**2) : 0.917 ; 1.500 REMARK 3 MAIN-CHAIN ANGLE (A**2) : 1.345 ; 2.000 REMARK 3 SIDE-CHAIN BOND (A**2) : 1.548 ; 2.000 REMARK 3 SIDE-CHAIN ANGLE (A**2) : 2.021 ; 2.500 REMARK 3 REMARK 3 BULK SOLVENT MODELING. REMARK 3 METHOD USED : NULL REMARK 3 KSOL : NULL REMARK 3 BSOL : NULL REMARK 3 REMARK 3 NCS MODEL : NULL REMARK 3 REMARK 3 NCS RESTRAINTS. RMS SIGMA/WEIGHT REMARK 3 GROUP 1 POSITIONAL (A) : NULL ; NULL REMARK 3 GROUP 1 B-FACTOR (A**2) : NULL ; NULL REMARK 3 REMARK 3 PARAMETER FILE 1 : PROTEIN_REP.PARAM REMARK 3 PARAMETER FILE 2 : WATER_REP.PARAM REMARK 3 PARAMETER FILE 3 : NULL REMARK 3 TOPOLOGY FILE 1 : PROTEIN.TOP REMARK 3 TOPOLOGY FILE 2 : WATER.TOP REMARK 3 TOPOLOGY FILE 3 : NULL REMARK 3 REMARK 3 OTHER REFINEMENT REMARKS: REFINEMENT AT EARLY STAGES UTILISED X REMARK 3 -PLOR AND REFMAC AND NCS RESTRAINTS WERE RELEASED AT THE FINAL REMARK 3 STAGES OF REFINEMENT THE SIDE CHAINS OF THE FOLLOWING RESIDUES REMARK 3 ARE DISORDERED ASN A 15, LYS A 51, LYS A 155, ARG B 49, LYS B 51, REMARK 3 ARG B 88, LYS B 155, LYS B 160 SER A 2 IS DISORDERED AND NOT REMARK 3 OBSERVED REMARK 4 REMARK 4 1QNH COMPLIES WITH FORMAT V. 3.30, 13-JUL-11 REMARK 100 REMARK 100 THIS ENTRY HAS BEEN PROCESSED BY PDBE ON 14-OCT-99. REMARK 100 THE DEPOSITION ID IS D_1290004212. REMARK 200 REMARK 200 EXPERIMENTAL DETAILS REMARK 200 EXPERIMENT TYPE : X-RAY DIFFRACTION REMARK 200 DATE OF DATA COLLECTION : NULL REMARK 200 TEMPERATURE (KELVIN) : 277.0 REMARK 200 PH : 7.70 REMARK 200 NUMBER OF CRYSTALS USED : 4 REMARK 200 REMARK 200 SYNCHROTRON (Y/N) : Y REMARK 200 RADIATION SOURCE : ESRF REMARK 200 BEAMLINE : BM14 REMARK 200 X-RAY GENERATOR MODEL : NULL REMARK 200 MONOCHROMATIC OR LAUE (M/L) : M REMARK 200 WAVELENGTH OR RANGE (A) : 0.98 REMARK 200 MONOCHROMATOR : NULL REMARK 200 OPTICS : NULL REMARK 200 REMARK 200 DETECTOR TYPE : IMAGE PLATE REMARK 200 DETECTOR MANUFACTURER : FUJI BAS-2000 IMAGE PLATE REMARK 200 INTENSITY-INTEGRATION SOFTWARE : DENZO REMARK 200 DATA SCALING SOFTWARE : SCALEPACK REMARK 200 REMARK 200 NUMBER OF UNIQUE REFLECTIONS : 24606 REMARK 200 RESOLUTION RANGE HIGH (A) : 2.100 REMARK 200 RESOLUTION RANGE LOW (A) : 24.000 REMARK 200 REJECTION CRITERIA (SIGMA(I)) : NULL REMARK 200 REMARK 200 OVERALL. REMARK 200 COMPLETENESS FOR RANGE (%) : 98.2 REMARK 200 DATA REDUNDANCY : 5.000 REMARK 200 R MERGE (I) : 0.07600 REMARK 200 R SYM (I) : NULL REMARK 200 FOR THE DATA SET : 17.8000 REMARK 200 REMARK 200 IN THE HIGHEST RESOLUTION SHELL. REMARK 200 HIGHEST RESOLUTION SHELL, RANGE HIGH (A) : 2.10 REMARK 200 HIGHEST RESOLUTION SHELL, RANGE LOW (A) : 2.15 REMARK 200 COMPLETENESS FOR SHELL (%) : 92.7 REMARK 200 DATA REDUNDANCY IN SHELL : 2.00 REMARK 200 R MERGE FOR SHELL (I) : 0.21300 REMARK 200 R SYM FOR SHELL (I) : NULL REMARK 200 FOR SHELL : 3.700 REMARK 200 REMARK 200 DIFFRACTION PROTOCOL: SINGLE WAVELENGTH REMARK 200 METHOD USED TO DETERMINE THE STRUCTURE: MOLECULAR REPLACEMENT REMARK 200 SOFTWARE USED: AMORE REMARK 200 STARTING MODEL: PDB ENTRY 1CWA REMARK 200 REMARK 200 REMARK: NULL REMARK 280 REMARK 280 CRYSTAL REMARK 280 SOLVENT CONTENT, VS (%): 55.00 REMARK 280 MATTHEWS COEFFICIENT, VM (ANGSTROMS**3/DA): 2.74 REMARK 280 REMARK 280 CRYSTALLIZATION CONDITIONS: PH 7.70 REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY REMARK 290 SYMMETRY OPERATORS FOR SPACE GROUP: P 21 21 2 REMARK 290 REMARK 290 SYMOP SYMMETRY REMARK 290 NNNMMM OPERATOR REMARK 290 1555 X,Y,Z REMARK 290 2555 -X,-Y,Z REMARK 290 3555 -X+1/2,Y+1/2,-Z REMARK 290 4555 X+1/2,-Y+1/2,-Z REMARK 290 REMARK 290 WHERE NNN -> OPERATOR NUMBER REMARK 290 MMM -> TRANSLATION VECTOR REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY TRANSFORMATIONS REMARK 290 THE FOLLOWING TRANSFORMATIONS OPERATE ON THE ATOM/HETATM REMARK 290 RECORDS IN THIS ENTRY TO PRODUCE CRYSTALLOGRAPHICALLY REMARK 290 RELATED MOLECULES. REMARK 290 SMTRY1 1 1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 1 0.000000 1.000000 0.000000 0.00000 REMARK 290 SMTRY3 1 0.000000 0.000000 1.000000 0.00000 REMARK 290 SMTRY1 2 -1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 2 0.000000 -1.000000 0.000000 0.00000 REMARK 290 SMTRY3 2 0.000000 0.000000 1.000000 0.00000 REMARK 290 SMTRY1 3 -1.000000 0.000000 0.000000 46.05500 REMARK 290 SMTRY2 3 0.000000 1.000000 0.000000 57.56000 REMARK 290 SMTRY3 3 0.000000 0.000000 -1.000000 0.00000 REMARK 290 SMTRY1 4 1.000000 0.000000 0.000000 46.05500 REMARK 290 SMTRY2 4 0.000000 -1.000000 0.000000 57.56000 REMARK 290 SMTRY3 4 0.000000 0.000000 -1.000000 0.00000 REMARK 290 REMARK 290 REMARK: NULL REMARK 300 REMARK 300 BIOMOLECULE: 1, 2 REMARK 300 SEE REMARK 350 FOR THE AUTHOR PROVIDED AND/OR PROGRAM REMARK 300 GENERATED ASSEMBLY INFORMATION FOR THE STRUCTURE IN REMARK 300 THIS ENTRY. THE REMARK MAY ALSO PROVIDE INFORMATION ON REMARK 300 BURIED SURFACE AREA. REMARK 350 REMARK 350 COORDINATES FOR A COMPLETE MULTIMER REPRESENTING THE KNOWN REMARK 350 BIOLOGICALLY SIGNIFICANT OLIGOMERIZATION STATE OF THE REMARK 350 MOLECULE CAN BE GENERATED BY APPLYING BIOMT TRANSFORMATIONS REMARK 350 GIVEN BELOW. BOTH NON-CRYSTALLOGRAPHIC AND REMARK 350 CRYSTALLOGRAPHIC OPERATIONS ARE GIVEN. REMARK 350 REMARK 350 BIOMOLECULE: 1 REMARK 350 SOFTWARE DETERMINED QUATERNARY STRUCTURE: DIMERIC REMARK 350 SOFTWARE USED: PQS REMARK 350 TOTAL BURIED SURFACE AREA: 1120 ANGSTROM**2 REMARK 350 SURFACE AREA OF THE COMPLEX: 9520 ANGSTROM**2 REMARK 350 CHANGE IN SOLVENT FREE ENERGY: -8.2 KCAL/MOL REMARK 350 APPLY THE FOLLOWING TO CHAINS: A, C REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 350 REMARK 350 BIOMOLECULE: 2 REMARK 350 SOFTWARE DETERMINED QUATERNARY STRUCTURE: DIMERIC REMARK 350 SOFTWARE USED: PQS REMARK 350 TOTAL BURIED SURFACE AREA: 1120 ANGSTROM**2 REMARK 350 SURFACE AREA OF THE COMPLEX: 9470 ANGSTROM**2 REMARK 350 CHANGE IN SOLVENT FREE ENERGY: -8.4 KCAL/MOL REMARK 350 APPLY THE FOLLOWING TO CHAINS: B, D REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 400 REMARK 400 COMPOUND REMARK 400 CYCLOSPORIN IS A CYCLIC UNDECAPEPTIDE. REMARK 400 HERE, CYCLOSPORIN A IS REPRESENTED BY THE SEQUENCE (SEQRES) REMARK 400 REMARK 400 GROUP: 1 REMARK 400 NAME: CYCLOSPORIN A REMARK 400 CHAIN: C, D REMARK 400 COMPONENT_1: PEPTIDE LIKE SEQUENCE RESIDUES 1 TO 11 REMARK 400 DESCRIPTION: CYCLOSPORIN IS A CYCLIC UNDECAPEPTIDE. REMARK 400 CYCLIZATION IS ACHIEVED BY LINKING THE N- AND REMARK 400 THE C- TERMINI. REMARK 400 REMARK 400 THE CYCLOSPORIN A IS CYCLIC PEPTIDE, A MEMBER OF IMMUNOSUPPRESSANT REMARK 400 CLASS. REMARK 400 REMARK 400 GROUP: 1 REMARK 400 NAME: CYCLOSPORIN A REMARK 400 CHAIN: C, D REMARK 400 COMPONENT_1: PEPTIDE LIKE POLYMER REMARK 400 DESCRIPTION: CYCLOSPORIN IS A CYCLIC UNDECAPEPTIDE. CYCLIZATION REMARK 400 IS ACHIEVED BY LINKING THE N- AND THE C- TERMINI. REMARK 465 REMARK 465 MISSING RESIDUES REMARK 465 THE FOLLOWING RESIDUES WERE NOT LOCATED IN THE REMARK 465 EXPERIMENT. (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN REMARK 465 IDENTIFIER; SSSEQ=SEQUENCE NUMBER; I=INSERTION CODE.) REMARK 465 REMARK 465 M RES C SSSEQI REMARK 465 SER A 2 REMARK 470 REMARK 470 MISSING ATOM REMARK 470 THE FOLLOWING RESIDUES HAVE MISSING ATOMS (M=MODEL NUMBER; REMARK 470 RES=RESIDUE NAME; C=CHAIN IDENTIFIER; SSEQ=SEQUENCE NUMBER; REMARK 470 I=INSERTION CODE): REMARK 470 M RES CSSEQI ATOMS REMARK 470 ASN A 15 CG OD1 ND2 REMARK 470 LYS A 51 CG CD CE NZ REMARK 470 LYS A 155 CG CD CE NZ REMARK 470 ARG B 49 CG CD NE CZ NH1 NH2 REMARK 470 LYS B 51 CG CD CE NZ REMARK 470 ARG B 88 CG CD NE CZ NH1 NH2 REMARK 470 LYS B 155 CG CD CE NZ REMARK 470 LYS B 160 CG CD CE NZ REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: TORSION ANGLES REMARK 500 REMARK 500 TORSION ANGLES OUTSIDE THE EXPECTED RAMACHANDRAN REGIONS: REMARK 500 (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN IDENTIFIER; REMARK 500 SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT:(10X,I3,1X,A3,1X,A1,I4,A1,4X,F7.2,3X,F7.2) REMARK 500 REMARK 500 EXPECTED VALUES: GJ KLEYWEGT AND TA JONES (1996). PHI/PSI- REMARK 500 CHOLOGY: RAMACHANDRAN REVISITED. STRUCTURE 4, 1395 - 1400 REMARK 500 REMARK 500 M RES CSSEQI PSI PHI REMARK 500 ASN A 15 -1.24 71.92 REMARK 500 ARG A 49 -122.03 -79.03 REMARK 500 PHE A 67 -80.25 -138.07 REMARK 500 SER A 116 -92.44 -140.76 REMARK 500 ARG B 49 -137.02 -93.77 REMARK 500 PHE B 67 -81.80 -137.50 REMARK 500 SER B 116 -92.82 -132.95 REMARK 500 MLE C 210 -166.69 -100.48 REMARK 500 MLE D 210 -167.73 -104.75 REMARK 500 REMARK 500 REMARK: NULL REMARK 525 REMARK 525 SOLVENT REMARK 525 REMARK 525 THE SOLVENT MOLECULES HAVE CHAIN IDENTIFIERS THAT REMARK 525 INDICATE THE POLYMER CHAIN WITH WHICH THEY ARE MOST REMARK 525 CLOSELY ASSOCIATED. THE REMARK LISTS ALL THE SOLVENT REMARK 525 MOLECULES WHICH ARE MORE THAN 5A AWAY FROM THE REMARK 525 NEAREST POLYMER CHAIN (M = MODEL NUMBER; REMARK 525 RES=RESIDUE NAME; C=CHAIN IDENTIFIER; SSEQ=SEQUENCE REMARK 525 NUMBER; I=INSERTION CODE): REMARK 525 REMARK 525 M RES CSSEQI REMARK 525 HOH A2008 DISTANCE = 6.15 ANGSTROMS REMARK 800 REMARK 800 SITE REMARK 800 SITE_IDENTIFIER: AC1 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR CHAIN C OF CYCLOSPORIN A REMARK 800 REMARK 800 SITE_IDENTIFIER: AC2 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR CHAIN D OF CYCLOSPORIN A REMARK 900 REMARK 900 RELATED ENTRIES REMARK 900 RELATED ID: 1BCK RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HUMAN CYCLOPHILIN A COMPLEXED WITH CYCLOSPORIN REMARK 900 C REMARK 900 RELATED ID: 1C5F RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF THE CYCLOPHILIN-LIKE DOMAIN FROM BRUGIA MALAYI REMARK 900 COMPLEXED WITH CYCLOSPORIN A REMARK 900 RELATED ID: 1CSA RELATED DB: PDB REMARK 900 SOLUTION STRUCTURE OF E.COLI CYCLOPHILIN (F112W) COMPLEXED WITH REMARK 900 CYCLOSPORIN A REMARK 900 RELATED ID: 1CWA RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HUMAN CYCLOPHILIN A COMPLEXED WITH CYCLOSPORIN REMARK 900 A REMARK 900 RELATED ID: 1CWB RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HUMAN CYCLOPHILIN A COMPLEXED WITH MODIFIED REMARK 900 CYCLOSPORIN A AT POSITION 5 REMARK 900 RELATED ID: 1CWC RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HUMAN CYCLOPHILIN A COMPLEXED WITH MODIFIED REMARK 900 CYCLOSPORIN A AT POSITION 8 REMARK 900 RELATED ID: 1CWF RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HUMAN CYCLOPHILIN A COMPLEXED WITH CYCLOSPORIN REMARK 900 D REMARK 900 RELATED ID: 1CWH RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HUMAN CYCLOPHILIN A COMPLEXED WITH CYCLOSPORIN REMARK 900 A MODIFIED AT POSITION 7 REMARK 900 RELATED ID: 1CWI RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HUMAN CYCLOPHILIN A COMPLEXED WITH MODIFIED REMARK 900 CYCLOSPORIN D AT POSITION 7 REMARK 900 RELATED ID: 1CWJ RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HUMAN CYCLOPHILIN A COMPLEXED WITH MODIFIED REMARK 900 CYCLOSPORIN D AT POSITIONS 5 AND 7. REMARK 900 RELATED ID: 1CWK RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HUMAN CYCLOPHILIN A COMPLEXED WITH MODIFIED REMARK 900 CYCLOSPORIN D AT POSITIONS 5 AND 7. REMARK 900 RELATED ID: 1CWL RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HUMAN CYCLOPHILIN A COMPLEXED WITH MODIFIED REMARK 900 CYCLOSPORIN A AT POSITION 8 REMARK 900 RELATED ID: 1CWM RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HUMAN CYCLOPHILIN A COMPLEXED WITH MODIFIED REMARK 900 CYCLOSPORIN A AT POSITION 8 REMARK 900 RELATED ID: 1CWO RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HUMAN CYCLOPHILIN A COMPLEXED WITH MODIFIED REMARK 900 CYCLOSPORIN C AT POSITIONS 1, AND 9 REMARK 900 RELATED ID: 1CYA RELATED DB: PDB REMARK 900 SOLUTION STRUCTURE OF HUMAN CYCLOPHILIN COMPLEXED WIYH CYCLOSPORIN A REMARK 900 RELATED ID: 1CYB RELATED DB: PDB REMARK 900 SOLUTION STRUCTURE OF HUMAN CYCLOPHILIN COMPLEXED WITH CYCLOSPORIN A REMARK 900 RELATED ID: 1CYN RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HUMAN CYCLOPHILIN B COMPLEXED WITH MODIFIED REMARK 900 CYCLOSPORIN A REMARK 900 RELATED ID: 1IKF RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF CTCLOSPORIN-FAB COMPLEX REMARK 900 RELATED ID: 1M63 RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF CALCINEURIN-CYCLOPHILIN-CYCLOSPORIN COMPLEX REMARK 900 RELATED ID: 1MF8 RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HUMAN CALCINEURIN COMPLEXED WITH HUMAN REMARK 900 CYCLOPHILIN AND CYCLOSPORIN A REMARK 900 RELATED ID: 1MIK RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HUMAN CYCLOPHILIN A COMPLEXED WITH MODIFIED REMARK 900 CYCLOSPORIN A AT POSITION 6 REMARK 900 RELATED ID: 1QNG RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF PLASMODIUM FALCIPARUM CYCLOPHILIN COMPLEXED REMARK 900 WITH CYCLOSPORIN A REMARK 900 RELATED ID: 1XQ7 RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF TRYPANOSOMA CRUZI CYCLOPHILIN COMPLEXED WITH REMARK 900 CYCLOSPORIN A REMARK 900 RELATED ID: 2ESL RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HUMAN CYCLOPHILIN C COMPLEXED WITH CYCLOSPORIN REMARK 900 A REMARK 900 RELATED ID: 2OJU RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HUMAN CYCLOPHILIN J COMPLEXED WITH CYCLOSPORIN REMARK 900 A REMARK 900 RELATED ID: 2POY RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF CRYPTOSPORIDIUM PARVUM IOWA II CYCLOPHILIN A REMARK 900 COMPLEXED WITH CYCLOSPORIN A REMARK 900 RELATED ID: 2RMA RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HUMAN CYCLOPHILIN A COMPLEXED WITH CYCLOSPORIN REMARK 900 A REMARK 900 RELATED ID: 2RMB RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HUMAN CYCLOPHILIN A COMPLEXED WITH MODIFIED REMARK 900 CYCLOSPORIN A AT POSITION 5 REMARK 900 RELATED ID: 2RMC RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF MURINE CYCLOPHILIN C COMPLEXED WITH REMARK 900 CYCLOSPORIN A REMARK 900 RELATED ID: 2WFJ RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF THE PPIASE DOMAIN OF HUMAN CYCLOPHILIN G REMARK 900 COMPLEXED WITH CYCLOSPORIN A REMARK 900 RELATED ID: 2X2C RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HUMAN ACETYL-CYPA COMPLEXED WITH CYCLOSPORINE A REMARK 900 RELATED ID: 2X7K RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF PPIL1 COMPLEXED WITH CYCLOSPORINE A REMARK 900 RELATED ID: 2Z6W RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HUMAN CYCLOPHILIN D IN COMPLEX WITH REMARK 900 CYCLOSPORIN A REMARK 900 RELATED ID: 3BO7 RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF CYCLOSPHILIN A FROM TOXOPLASMA GONDII REMARK 900 COMPLEXED WIT CYCLOSPORIN A REMARK 900 RELATED ID: 3CYS RELATED DB: PDB REMARK 900 SOLUTION STRUCTURE OF THE HUMAN CYCLOSPORIN A COMPLEXED WITH REMARK 900 CYCLOSPORIN A REMARK 900 RELATED ID: 3EOV RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF CYCLOPHILIN FROM LEISHMANIA DONOVANI COMPLEXED REMARK 900 WITH CYCLOSPORIN A DBREF 1QNH A 2 171 UNP Q25756 Q25756 2 171 DBREF 1QNH B 2 171 UNP Q25756 Q25756 2 171 DBREF 1QNH C 201 211 NOR NOR00033 NOR00033 1 11 DBREF 1QNH D 201 211 NOR NOR00033 NOR00033 1 11 SEQADV 1QNH LEU A 120 UNP Q25756 PHE 120 ENGINEERED MUTATION SEQADV 1QNH TRP A 171 UNP Q25756 LEU 171 ENGINEERED MUTATION SEQADV 1QNH LEU B 120 UNP Q25756 PHE 120 ENGINEERED MUTATION SEQADV 1QNH TRP B 171 UNP Q25756 LEU 171 ENGINEERED MUTATION SEQRES 1 A 170 SER LYS ARG SER LYS VAL PHE PHE ASP ILE SER ILE ASP SEQRES 2 A 170 ASN SER ASN ALA GLY ARG ILE ILE PHE GLU LEU PHE SER SEQRES 3 A 170 ASP ILE THR PRO ARG THR CYS GLU ASN PHE ARG ALA LEU SEQRES 4 A 170 CYS THR GLY GLU LYS ILE GLY SER ARG GLY LYS ASN LEU SEQRES 5 A 170 HIS TYR LYS ASN SER ILE PHE HIS ARG ILE ILE PRO GLN SEQRES 6 A 170 PHE MET CYS GLN GLY GLY ASP ILE THR ASN GLY ASN GLY SEQRES 7 A 170 SER GLY GLY GLU SER ILE TYR GLY ARG SER PHE THR ASP SEQRES 8 A 170 GLU ASN PHE ASN MET LYS HIS ASP GLN PRO GLY LEU LEU SEQRES 9 A 170 SER MET ALA ASN ALA GLY PRO ASN THR ASN SER SER GLN SEQRES 10 A 170 PHE LEU ILE THR LEU VAL PRO CYS PRO TRP LEU ASP GLY SEQRES 11 A 170 LYS HIS VAL VAL PHE GLY LYS VAL ILE GLU GLY MET ASN SEQRES 12 A 170 VAL VAL ARG GLU MET GLU LYS GLU GLY ALA LYS SER GLY SEQRES 13 A 170 TYR VAL LYS ARG SER VAL VAL ILE THR ASP CYS GLY GLU SEQRES 14 A 170 TRP SEQRES 1 B 170 SER LYS ARG SER LYS VAL PHE PHE ASP ILE SER ILE ASP SEQRES 2 B 170 ASN SER ASN ALA GLY ARG ILE ILE PHE GLU LEU PHE SER SEQRES 3 B 170 ASP ILE THR PRO ARG THR CYS GLU ASN PHE ARG ALA LEU SEQRES 4 B 170 CYS THR GLY GLU LYS ILE GLY SER ARG GLY LYS ASN LEU SEQRES 5 B 170 HIS TYR LYS ASN SER ILE PHE HIS ARG ILE ILE PRO GLN SEQRES 6 B 170 PHE MET CYS GLN GLY GLY ASP ILE THR ASN GLY ASN GLY SEQRES 7 B 170 SER GLY GLY GLU SER ILE TYR GLY ARG SER PHE THR ASP SEQRES 8 B 170 GLU ASN PHE ASN MET LYS HIS ASP GLN PRO GLY LEU LEU SEQRES 9 B 170 SER MET ALA ASN ALA GLY PRO ASN THR ASN SER SER GLN SEQRES 10 B 170 PHE LEU ILE THR LEU VAL PRO CYS PRO TRP LEU ASP GLY SEQRES 11 B 170 LYS HIS VAL VAL PHE GLY LYS VAL ILE GLU GLY MET ASN SEQRES 12 B 170 VAL VAL ARG GLU MET GLU LYS GLU GLY ALA LYS SER GLY SEQRES 13 B 170 TYR VAL LYS ARG SER VAL VAL ILE THR ASP CYS GLY GLU SEQRES 14 B 170 TRP SEQRES 1 C 11 DAL MLE MLE MVA BMT ABA SAR MLE VAL MLE ALA SEQRES 1 D 11 DAL MLE MLE MVA BMT ABA SAR MLE VAL MLE ALA MODRES 1QNH MLE C 202 LEU N-METHYLLEUCINE MODRES 1QNH MLE C 203 LEU N-METHYLLEUCINE MODRES 1QNH MVA C 204 VAL N-METHYLVALINE MODRES 1QNH BMT C 205 THR MODRES 1QNH ABA C 206 ALA ALPHA-AMINOBUTYRIC ACID MODRES 1QNH SAR C 207 GLY SARCOSINE MODRES 1QNH MLE C 208 LEU N-METHYLLEUCINE MODRES 1QNH MLE C 210 LEU N-METHYLLEUCINE MODRES 1QNH MLE D 202 LEU N-METHYLLEUCINE MODRES 1QNH MLE D 203 LEU N-METHYLLEUCINE MODRES 1QNH MVA D 204 VAL N-METHYLVALINE MODRES 1QNH BMT D 205 THR MODRES 1QNH ABA D 206 ALA ALPHA-AMINOBUTYRIC ACID MODRES 1QNH SAR D 207 GLY SARCOSINE MODRES 1QNH MLE D 208 LEU N-METHYLLEUCINE MODRES 1QNH MLE D 210 LEU N-METHYLLEUCINE HET DAL C 201 5 HET MLE C 202 9 HET MLE C 203 9 HET MVA C 204 8 HET BMT C 205 13 HET ABA C 206 6 HET SAR C 207 5 HET MLE C 208 9 HET MLE C 210 9 HET DAL D 201 5 HET MLE D 202 9 HET MLE D 203 9 HET MVA D 204 8 HET BMT D 205 13 HET ABA D 206 6 HET SAR D 207 5 HET MLE D 208 9 HET MLE D 210 9 HETNAM DAL D-ALANINE HETNAM MLE N-METHYLLEUCINE HETNAM MVA N-METHYLVALINE HETNAM BMT 4-METHYL-4-[(E)-2-BUTENYL]-4,N-METHYL-THREONINE HETNAM ABA ALPHA-AMINOBUTYRIC ACID HETNAM SAR SARCOSINE FORMUL 3 DAL 2(C3 H7 N O2) FORMUL 3 MLE 8(C7 H15 N O2) FORMUL 3 MVA 2(C6 H13 N O2) FORMUL 3 BMT 2(C10 H19 N O3) FORMUL 3 ABA 2(C4 H9 N O2) FORMUL 3 SAR 2(C3 H7 N O2) FORMUL 5 HOH *213(H2 O) HELIX 1 1 THR A 30 GLY A 43 1 14 HELIX 2 2 CYS A 126 ASP A 130 5 5 HELIX 3 3 GLY A 142 LYS A 151 1 10 HELIX 4 4 THR B 30 GLY B 43 1 14 HELIX 5 5 CYS B 126 ASP B 130 5 5 HELIX 6 6 GLY B 142 LYS B 151 1 10 SHEET 1 AA 8 ARG A 62 ILE A 64 0 SHEET 2 AA 8 MET A 68 GLY A 71 -1 O MET A 68 N ILE A 64 SHEET 3 AA 8 PHE A 119 THR A 122 -1 O PHE A 119 N GLY A 71 SHEET 4 AA 8 LEU A 104 MET A 107 -1 O LEU A 104 N THR A 122 SHEET 5 AA 8 VAL A 135 GLU A 141 -1 N PHE A 136 O LEU A 105 SHEET 6 AA 8 SER A 16 LEU A 25 -1 O ILE A 22 N ILE A 140 SHEET 7 AA 8 LYS A 6 ILE A 13 -1 O VAL A 7 N PHE A 23 SHEET 8 AA 8 VAL A 163 GLU A 170 -1 O VAL A 164 N SER A 12 SHEET 1 AB 2 LYS A 45 ILE A 46 0 SHEET 2 AB 2 ASN A 52 LEU A 53 -1 O LEU A 53 N LYS A 45 SHEET 1 BA 8 ARG B 62 ILE B 64 0 SHEET 2 BA 8 MET B 68 GLY B 71 -1 O MET B 68 N ILE B 64 SHEET 3 BA 8 PHE B 119 THR B 122 -1 O PHE B 119 N GLY B 71 SHEET 4 BA 8 LEU B 104 MET B 107 -1 O LEU B 104 N THR B 122 SHEET 5 BA 8 VAL B 135 GLU B 141 -1 N PHE B 136 O LEU B 105 SHEET 6 BA 8 SER B 16 LEU B 25 -1 O ILE B 22 N ILE B 140 SHEET 7 BA 8 SER B 5 ILE B 13 -1 O SER B 5 N LEU B 25 SHEET 8 BA 8 VAL B 163 GLU B 170 -1 O VAL B 164 N SER B 12 LINK C DAL C 201 N MLE C 202 1555 1555 1.38 LINK N DAL C 201 C ALA C 211 1555 1555 1.34 LINK C MLE C 202 N MLE C 203 1555 1555 1.35 LINK C MLE C 203 N MVA C 204 1555 1555 1.34 LINK C MVA C 204 N BMT C 205 1555 1555 1.37 LINK C BMT C 205 N ABA C 206 1555 1555 1.34 LINK C ABA C 206 N SAR C 207 1555 1555 1.36 LINK C SAR C 207 N MLE C 208 1555 1555 1.37 LINK C MLE C 208 N VAL C 209 1555 1555 1.33 LINK C VAL C 209 N MLE C 210 1555 1555 1.35 LINK C MLE C 210 N ALA C 211 1555 1555 1.33 LINK C DAL D 201 N MLE D 202 1555 1555 1.38 LINK N DAL D 201 C ALA D 211 1555 1555 1.35 LINK C MLE D 202 N MLE D 203 1555 1555 1.34 LINK C MLE D 203 N MVA D 204 1555 1555 1.34 LINK C MVA D 204 N BMT D 205 1555 1555 1.36 LINK C BMT D 205 N ABA D 206 1555 1555 1.34 LINK C ABA D 206 N SAR D 207 1555 1555 1.35 LINK C SAR D 207 N MLE D 208 1555 1555 1.37 LINK C MLE D 208 N VAL D 209 1555 1555 1.33 LINK C VAL D 209 N MLE D 210 1555 1555 1.35 LINK C MLE D 210 N ALA D 211 1555 1555 1.33 SITE 1 AC1 14 ARG A 62 PHE A 67 GLN A 70 GLY A 79 SITE 2 AC1 14 ALA A 108 ASN A 109 GLN A 118 LEU A 120 SITE 3 AC1 14 TRP A 128 HIS A 133 ALA B 110 HOH C2002 SITE 4 AC1 14 HOH C2003 BMT D 205 SITE 1 AC2 19 ARG A 88 ALA A 110 HOH A2037 ARG B 62 SITE 2 AC2 19 PHE B 67 GLN B 70 GLY B 79 ALA B 108 SITE 3 AC2 19 ASN B 109 GLN B 118 LEU B 120 TRP B 128 SITE 4 AC2 19 LEU B 129 HIS B 133 ABA C 206 SAR C 207 SITE 5 AC2 19 HOH D2002 HOH D2003 HOH D2004 CRYST1 92.110 115.120 39.020 90.00 90.00 90.00 P 21 21 2 8 ORIGX1 1.000000 0.000000 0.000000 0.00000 ORIGX2 0.000000 1.000000 0.000000 0.00000 ORIGX3 0.000000 0.000000 1.000000 0.00000 SCALE1 0.010857 0.000000 0.000000 0.00000 SCALE2 0.000000 0.008687 0.000000 0.00000 SCALE3 0.000000 0.000000 0.025628 0.00000 MTRIX1 1 -0.163350 -0.986060 0.031820 63.67295 1 MTRIX2 1 0.964890 -0.166400 -0.203210 72.66035 1 MTRIX3 1 0.205670 -0.002500 0.978620 11.18299 1